US Bancorp’s Lifecore Biomedical LFCR Stock Holding History

US Bancorp’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-251	Closed	-$3K	–	4148
2022 Q1	$3K	Buy	+251	New	+$2.79K	﹤0.01%	3748
2020 Q1	–	Sell	-5,000	Closed	-$57K	–	3739
2019 Q4	$57K	Buy	+5,000	New	+$53.2K	﹤0.01%	2413
2017 Q3	–	Sell	-109	Closed	-$2K	–	3608
2017 Q2	$2K	Hold	109	–	–	﹤0.01%	3396
2017 Q1	$1K	Sell	109 -483	-82%	-$6.12K	﹤0.01%	3473
2016 Q4	$8K	Hold	592	–	–	﹤0.01%	3082
2016 Q3	$8K	Hold	592	–	–	﹤0.01%	3051
2016 Q2	$6K	Hold	592	–	–	﹤0.01%	3132
2016 Q1	$6K	Hold	592	–	–	﹤0.01%	3128
2015 Q4	$7K	Hold	592	–	–	﹤0.01%	3141
2015 Q3	$7K	Hold	592	–	–	﹤0.01%	3168
2015 Q2	$9K	Hold	592	–	–	﹤0.01%	3166
2015 Q1	$8K	Hold	592	–	–	﹤0.01%	3178
2014 Q4	$8K	Sell	592 -800	-57%	-$10.3K	﹤0.01%	3169
2014 Q3	$17K	Sell	1,392 -890	-39%	-$11.1K	﹤0.01%	2905
2014 Q2	$29K	Buy	2,282 +1,351	+145%	+$15.9K	﹤0.01%	2712
2014 Q1	$10K	Hold	931	–	–	﹤0.01%	3040
2013 Q4	$11K	Hold	931	–	–	﹤0.01%	2969
2013 Q3	$11K	Hold	931	–	–	﹤0.01%	2855
2013 Q2	$12K	Buy	+931	New	+$12.9K	﹤0.01%	2819

Other funds holding LFCR

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

ICM

ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CSC

Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

US Bancorp's LFCR Position: Q2 2022 in Review

US Bancorp sold out of Lifecore Biomedical (LFCR) in Q2 2022, closing a stake of 251 shares — an estimated $3K sold.

US Bancorp first reported a position in LFCR in Q2 2013 and held it in 19 quarters. The position peaked at $57K in Q4 2019. 90 funds tracked by Wall St. Rank hold LFCR as of Q2 2022.

US Bancorp reported no remaining Lifecore Biomedical position as of Q2 2022 after selling out during the quarter.
US Bancorp sold 251 Lifecore Biomedical shares in Q2 2022, an estimated $3K.
US Bancorp first reported a position in Lifecore Biomedical in Q2 2013 and held it in 19 quarters.
US Bancorp's Lifecore Biomedical position peaked at $57K in Q4 2019.
90 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2022.

Based on US Bancorp's 13F filing for Q2 2022, filed 1 Aug 2022.